H.C. Wainwright Has Just Reaffirmed $3.0000 Target Price Per Share on Vascular Biogenics (NASDAQ:VBLT) stock, While They’ve Also Reiterated Their “Hold” Rating

May 18, 2018 - By Stephen Andrade

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Vascular Biogenics (NASDAQ:VBLT) Rating Reaffirmed

New York: In a research note revealed to investors and clients on 18 May, H.C. Wainwright reiterated their “Hold” rating on Vascular Biogenics (NASDAQ:VBLT) shares. They now have a $3.0000 target price per share on the firm. H.C. Wainwright’s target gives a potential upside of 39.53 % from the company’s last stock close.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 4 analysts covering Vascular Biogenics (NASDAQ:VBLT), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Vascular Biogenics had 5 analyst reports since March 8, 2018 according to SRatingsIntel. As per Thursday, March 8, the company rating was downgraded by H.C. Wainwright. The stock has “Hold” rating by Piper Jaffray on Thursday, March 8. The stock has “Hold” rating by H.C. Wainwright on Thursday, March 22. The rating was downgraded by JMP Securities to “Hold” on Thursday, March 8. The company was downgraded on Friday, March 9 by Chardan Capital Markets.

The stock decreased 2.27% or $0.05 during the last trading session, reaching $2.15. About 10,018 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has declined 59.29% since May 18, 2017 and is downtrending. It has underperformed by 70.84% the S&P500.

Analysts await Vascular Biogenics Ltd. (NASDAQ:VBLT) to report earnings on May, 21. They expect $-0.21 earnings per share, down 10.53 % or $0.02 from last year’s $-0.19 per share. After $0.24 actual earnings per share reported by Vascular Biogenics Ltd. for the previous quarter, Wall Street now forecasts -187.50 % negative EPS growth.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $64.28 million. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

More notable recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018, also Globenewswire.com with their article: “VBL Therapeutics Announces First Quarter 2018 Financial Results” published on May 17, 2018, Benzinga.com published: “Earnings Scheduled For May 17, 2018” on May 17, 2018. More interesting news about Vascular Biogenics Ltd. (NASDAQ:VBLT) were released by: Seekingalpha.com and their article: “VBL Therapeutics’ (VBLT) CEO Dror Harats on Q1 2018 Results – Earnings Call Transcript” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “24 Stocks Moving In Friday’s Pre-Market Session” with publication date: May 18, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.